Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers-Reference-Cited by-同舟云学术

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers

Published:2018-10 Issue:10 Volume:13 Page:1595-1601
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Drilon Alexander,Lin Jessica J.,Filleron Thomas,Ni Ai,Milia Julie,Bergagnini Isabella,Hatzoglou Vaios,Velcheti Vamsidhar,Offin Michael^ORCID,Li Bob,Carbone David P.,Besse Benjamin,Mok Tony,Awad Mark M.,Wolf Jurgen,Owen Dwight,Camidge D. Ross,Riely Gregory J.,Peled Nir,Kris Mark G.,Mazieres Julien,Gainor Justin F.,Gautschi Oliver

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes;Drilon;Nat Rev Clin Oncol,2018

2. Cabozantinib in patients with advanced RET-rearranged non–small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial;Drilon;Lancet Oncol,2016

3. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial;Yoh;Lancet Respir Med,2017

4. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial;Lee;Ann Oncol,2017

5. Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung;Velcheti;Ann Oncol,2016

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years;Journal of Clinical Oncology;2024-09-04

2. Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report;Case Reports in Oncology;2024-08-27

3. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

4. Evolution of therapy for ALK-positive lung carcinomas: Application of third-generation ALK inhibitors in real clinical practice;Meditsinskiy sovet = Medical Council;2024-07-24

5. CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer;Journal of Clinical Oncology;2024-07-20